Authoritative Expert Joins Again—Professor Xu Qin from the Department of Gynecological Oncology Radi

Authoritative Expert Joins Again—Professor Xu Qin from the Department of Gynecological Oncology Radiotherapy at Fujian Cancer Hospital Joins Our Institution

On August 15, Professor Xu Qin from the Department of Gynecological Oncology Radiotherapy at Fujian Cancer Hospital officially joined the Lanzhou Heavy Ion Center of Gansu Wuwei Tumor Hospital. Her addition infuses new and strong momentum into the development of the Lanzhou Heavy Ion Center in the field of cancer treatment.

As a seasoned expert in radiotherapy, Professor Xu Qin holds multiple distinguished titles: Chief Physician in the Department of Gynecological Oncology Radiotherapy at Fujian Cancer Hospital, Medical Doctor, Doctoral Supervisor, Sub-specialty Director, and Ph.D. graduate from Kobe University School of Medicine in Japan. She is recognized as a candidate for Fujian's Hundred, Thousand, and Ten Thousand Talent Program and an Outstanding Young Talent of Fujian Province. She also serves as a Standing Committee Member of the Cervical Cancer Professional Committee of the Chinese Anti-Cancer Association, Standing Committee Member of the Gynecological Oncology Integrated Rehabilitation Professional Committee, and Standing Committee Member of the Brachytherapy Professional Committee. She is particularly renowned for her expertise in the specialized diagnosis and treatment of gynecological tumors such as cervical cancer, endometrial cancer, and ovarian cancer, earning high repute and widespread influence in the industry.

Professor Xu Qin’s joining marks a significant achievement for the Lanzhou Heavy Ion Center of Gansu Wuwei Tumor Hospital in advancing its heavy ion treatment alliance and establishing 50 expert workstations. The Lanzhou Heavy Ion Center is the second clinical application center in China operated by Gansu Wuwei Tumor Hospital to utilize domestically developed heavy ion technology. The center launched its second-generation heavy ion tumor treatment system on November 15, 2024. To date, it has treated over 270 patients with photon and heavy ion therapies, covering cancers such as lung cancer, pancreatic cancer, liver cancer, and glioblastoma. The hospital aims to build a comprehensive, full-life-cycle cancer treatment system, offering departments including Radiotherapy, Medical Oncology/Hematology, Surgical Oncology, Integrated Traditional Chinese and Western Medicine for Cancer Rehabilitation, Critical Care Medicine, Digestive Endoscopy Center, Imaging Department, Laboratory Medicine, Ultrasonography, Blood Bank, and Hematology Center Laboratory. Services span photon radiotherapy, chemotherapy, heavy ion therapy, medical and surgical comprehensive treatments, alongside imaging, laboratory testing, ultrasonography, and bone marrow cytomorphology examinations.

During ward rounds, Professor Xu Qin meticulously reviewed each patient’s condition and treatment progress, engaging in in-depth discussions with radiotherapy physicians. Based on individual cases, she provided precise and personalized treatment recommendations. She emphasized that cancer treatment is a comprehensive and complex process, requiring holistic consideration of the patient’s physical condition, tumor type, staging, and other factors to tailor the most suitable therapeutic plan.

Professor Xu Qin’s addition will significantly enhance the disciplinary development and clinical capabilities of the Lanzhou Heavy Ion Center. Looking ahead, the center will continue to steadfastly promote the heavy ion treatment alliance and the 50 expert workstations, steadily improving its comprehensive strength. Under the leadership of outstanding experts such as Xu Qin, Xu Bo, Lan Shengmin, Yu Zhilong, and Fan Ruitai, the Lanzhou Heavy Ion Center is poised to achieve even more remarkable accomplishments in cancer treatment, bringing new hope and dawn to patients.

Lanzhou Heavy Ion Center

Gansu Wuwei Cancer Hospital is a state-owned public Grade A tertiary specialized cancer hospital. The Lanzhou Heavy Ion Center is the second clinical application center in China operated by Gansu Wuwei Cancer Hospital to utilize domestically developed heavy ion technology. Together with the first Chinese heavy ion treatment system, the second-generation heavy ion tumor treatment system commenced clinical operations at the Lanzhou Heavy Ion Center on November 15, 2024. To date, the center has treated over 270 patients with photon and heavy ion therapies, covering cancers such as lung cancer, pancreatic cancer, liver cancer, and glioblastoma.

The Lanzhou Heavy Ion Center has established an elite talent system, forming expert workstations led by 50 top industry authorities, including Shen Wenjiang, Lifetime Honorary Professor of the Department of Radiation Oncology at Peking University Health Science Center, and Professor Xu Bo, Standing Committee Member of the Chinese Medical Association's Radiation Oncology Branch. Professor Wang Junjie, Chairman of the Chinese Medical Association's Radiation Oncology Branch, serves as the hospital director, providing robust technical support for heavy ion therapy.

Additionally, the center is equipped with cutting-edge medical devices such as the Varian VitalBeam medical linear accelerator, Elekta Infinity four-dimensional image-guided linear accelerator, 3.0T simulation positioning MRI, GE Revolution 256-slice high-end CT, and the Varian iridium-192 imported afterloader. These advanced facilities lay a solid foundation for heavy ion therapy, ensuring high efficiency and precision throughout the treatment process.

Aiming to build a comprehensive, full-life-cycle cancer treatment system, the hospital has established departments including Radiotherapy, Medical Oncology/Hematology, Surgical Oncology, Integrated Traditional Chinese and Western Medicine for Cancer Rehabilitation, Critical Care Medicine, Digestive Endoscopy Center, Imaging Department, Laboratory Medicine, Ultrasonography, Blood Bank, and Hematology Center Laboratory. Services encompass photon radiotherapy, chemotherapy, heavy ion therapy, medical and surgical comprehensive treatments, alongside imaging, laboratory testing, ultrasonography, and bone marrow cytomorphology examinations.